CSPC Pharmaceutical Group (HKSE:01093) 3-Year EPS without NRI Growth Rate : 3.60% (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is CSPC Pharmaceutical Group 3-Year EPS without NRI Growth Rate?

CSPC Pharmaceutical Group's EPS without NRI for the three months ended in Dec. 2023 was HK$0.13.

During the past 12 months, CSPC Pharmaceutical Group's average EPS without NRI Growth Rate was -4.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was 3.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 14.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 23.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of CSPC Pharmaceutical Group was 303.70% per year. The lowest was -60.80% per year. And the median was 24.10% per year.

Competitive Comparison of CSPC Pharmaceutical Group's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSPC Pharmaceutical Group's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's 3-Year EPS without NRI Growth Rate falls into.

CSPC Pharmaceutical Group 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

CSPC Pharmaceutical Group (HKSE:01093) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

CSPC Pharmaceutical Group 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of CSPC Pharmaceutical Group's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CSPC Pharmaceutical Group (HKSE:01093) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (HKSE:01093) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

CSPCY:USA CHJTF:USA CVG:Germany

Address

No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035

Website

https://www.cspc.com.hk

CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.

CSPC Pharmaceutical Group (HKSE:01093) Headlines

No Headlines